These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24528518)

  • 41. The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa.
    Kamya MR; Byakika-Kibwika P; Gasasira AF; Havlir D; Rosenthal PJ; Dorsey G; Achan J
    Future Virol; 2012; 7(7):699-708. PubMed ID: 23293660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
    Scarsi KK; Fehintola FA; Ma Q; Aweeka FT; Darin KM; Morse GD; Akinola IT; Adedeji WA; Lindegardh N; Tarning J; Ojengbede O; Adewole IF; Taiwo B; Murphy RL; Akinyinka OO; Parikh S
    J Antimicrob Chemother; 2014 May; 69(5):1370-6. PubMed ID: 24446424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human immunodeficiency virus (HIV) and malaria interaction in sub-Saharan Africa: the collision of two Titans.
    Idemyor V
    HIV Clin Trials; 2007; 8(4):246-53. PubMed ID: 17720665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients.
    Abgrall S; Le Bel J; Lele N; Laouénan C; Eychenne N; Mentré F; Peytavin G; Bouchaud O;
    HIV Clin Trials; 2013; 14(6):313-8. PubMed ID: 24334184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Frequent malaria illness episodes in two Malawian patients on antiretroviral therapy soon after stopping cotrimoxazole preventive therapy.
    Nyangulu WJ; Mwinjiwa E; Divala TH; Mungwira RG; Nyirenda O; Kanjala M; Mbambo G; Mallewa J; Taylor TE; Laurens MB; Laufer MK; van Oosterhout JJ
    Malawi Med J; 2017 Mar; 29(1):57-60. PubMed ID: 28567199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial.
    Sandison TG; Homsy J; Arinaitwe E; Wanzira H; Kakuru A; Bigira V; Kalamya J; Vora N; Kublin J; Kamya MR; Dorsey G; Tappero JW
    BMJ; 2011 Mar; 342():d1617. PubMed ID: 21454456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
    Porter KA; Cole SR; Eron JJ; Zheng Y; Hughes MD; Lockman S; Poole C; Skinner-Adams TS; Hosseinipour M; Shaffer D; D'Amico R; Sawe FK; Siika A; Stringer E; Currier JS; Chipato T; Salata R; McCarthy JS; Meshnick SR
    Antimicrob Agents Chemother; 2012 Feb; 56(2):995-1000. PubMed ID: 22123685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. UK malaria treatment guidelines 2016.
    Lalloo DG; Shingadia D; Bell DJ; Beeching NJ; Whitty CJM; Chiodini PL;
    J Infect; 2016 Jun; 72(6):635-649. PubMed ID: 26880088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lopinavir/ritonavir enhanced the antimalarial activity of amodiaquine and artesunate in a mouse model of Plasmodium berghei.
    Abiodun OO; Gbimadee N; Gbotosho GO
    J Chemother; 2016 Dec; 28(6):482-486. PubMed ID: 26900802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Malaria Surveillance - United States, 2017.
    Mace KE; Lucchi NW; Tan KR
    MMWR Surveill Summ; 2021 Mar; 70(2):1-35. PubMed ID: 33735166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of two antifolate prophylactic strategies against malaria in HIV-positive pregnant women in Bangui, Central African Republic: study protocol for a randomized controlled trial (MACOMBA).
    Manirakiza A; Sepou A; Serdouma E; Gondje S; Bata GG; Moussa S; Boulay A; Moyen JM; Sakanga O; Le-Fouler L; Kazanji M; Vray M
    Trials; 2013 Aug; 14():255. PubMed ID: 23945130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Artemisinin-based combination therapy for treating uncomplicated malaria.
    Sinclair D; Zani B; Donegan S; Olliaro P; Garner P
    Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD007483. PubMed ID: 19588433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data.
    Bretscher MT; Dahal P; Griffin J; Stepniewska K; Bassat Q; Baudin E; D'Alessandro U; Djimde AA; Dorsey G; Espié E; Fofana B; González R; Juma E; Karema C; Lasry E; Lell B; Lima N; Menéndez C; Mombo-Ngoma G; Moreira C; Nikiema F; Ouédraogo JB; Staedke SG; Tinto H; Valea I; Yeka A; Ghani AC; Guerin PJ; Okell LC
    BMC Med; 2020 Feb; 18(1):47. PubMed ID: 32098634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.
    Clark TD; Njama-Meya D; Nzarubara B; Maiteki-Sebuguzi C; Greenhouse B; Staedke SG; Kamya MR; Dorsey G; Rosenthal PJ
    PLoS One; 2010 Jul; 5(7):e11759. PubMed ID: 20689585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses.
    Haynes RK; Cheu KW; N'Da D; Coghi P; Monti D
    Infect Disord Drug Targets; 2013 Aug; 13(4):217-77. PubMed ID: 24304352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
    Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.